MedTrace Logo

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

NCT02710149 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-06-25

No results posted yet for this study

Summary

The main purpose of this study is to explore the therapeutic effect of CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B cell malignancies.

Conditions

Interventions

BIOLOGICAL

Anti-CD20-CAR-transduced T cells

Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • Cheng Qian, MD, PhD · Biotherapy Center of Southwest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-03-31
Completion
2021-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710149 on ClinicalTrials.gov